Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

NCT02168686 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Alpha 1-Antitrypsin Deficiency

Interventions

GENETIC: ADVM-043

Sponsor

Adverum Biotechnologies, Inc.